Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice
Autor: | Eliseo Martínez-García, Enrique Herrera-Ceballos, Gustavo G. Garriga‐Martina, Enrique Herrera-Acosta, Jorge Alonso Suarez-Perez |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Dermatology Biologic treatment Antibodies Monoclonal Humanized Severity of Illness Index 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Psoriasis Area and Severity Index Psoriasis Internal medicine Medicine Humans business.industry Moderate to severe psoriasis Antibodies Monoclonal Retrospective cohort study General Medicine medicine.disease humanities Ixekizumab Treatment Outcome 030220 oncology & carcinogenesis Secukinumab business |
Zdroj: | Dermatologic therapyREFERENCES. 33(3) |
ISSN: | 1529-8019 |
Popis: | There are no studies which directly compare efficacy in Psoriasis Area and Severity Index (PASI) response of secukinumab and ixekizumab. The main aim of this study was to compare the efficacy and safety of both drugs used to treat moderate-to-severe psoriasis patients over 52 weeks. Secondary objectives were to identify which factors related to prior biologic treatment influenced their efficacy and analyze data obtained at 12 weeks. A retrospective observational study was carried out, in which a group of the first 59 patients treated with secukinumab after its commercialization, was compared with another group of the first 29 patients treated with ixekizumab. The PASI 75, 90, and 100 response obtained at 52 weeks was 64.4%, 49.2%, and 41.4% for secukinumab and 75.9%, 62.1%, and 41.4% for ixekizumab, respectively, with no statistically significant differences. Regarding previous biological treatment, both treatments showed a decrease in efficacy as the number of prior biologics increases. No differences were found between secukinumab and ixekizumab in bio-naive or bio-experienced patients, with the exception of a higher PASI 75 response at week 52 for ixekizumab in those patients with two or more previous biologics (P = .039) Secukinumab and ixekizumab have demonstrated high efficacy and safety, with no statistically significant differences. |
Databáze: | OpenAIRE |
Externí odkaz: |